From Discovery to Remission: How Agentic AI Is Reshaping the Oncology Continuum

From Discovery to Remission: How Agentic AI Is Reshaping the Oncology Continuum

Skip to content

Blog / Healthcare & Life Sciences / From Discovery to Remission: How Agentic AI Is Reshaping the Oncology Continuum

Oct 15, 2026 / 8 min read Healthcare & Life Sciences Copy post link Open in Claude Open in ChatGPT

From Discovery to Remission: How Agentic AI Is Reshaping the Oncology Continuum

Murali Gandhirajan

While researchers and care teams have been tackling the challenge of breast and other cancers for decades, today something is genuinely different in how organizations fight cancer. I've spent time with oncology researchers, health systems and life sciences companies, and overwhelmingly, the conversation has shifted from “We have a lot of data” and “How do we organize our data?” to “What can our systems do with it?”

Oncology generates more heterogeneous, high-stakes data than almost any other domain. Genomic sequences, pathology images, clinical notes, claims records and wearable signals have historically worked against clinicians rather than for them, fragmented across systems and slow to assemble when decisions matter most.

Agentic AI — systems that reason, plan and act across multistep workflows — is beginning to close that gap across the oncology continuum, moving healthcare and life sciences from siloed data toward AI experimentation and, further, measurable impact. This post follows the journey from the lab to survivorship, highlighting organizations moving this work forward.

Five stages, five long-standing bottlenecks

The oncology continuum has five connected stages, each with a long-standing data problem. Discovery and research teams rely on molecular and genomic data sets that remain siloed. Screening and early detection bring together imaging, biomarkers, electronic health record (EHR) data and family history only with difficulty. Diagnosis and treatment planning often require tumor boards to assemble patient profiles manually and incompletely. Treatment and care coordination depend on multimodal real-world data fragmented across sites and systems. Remission and survivorship generate evidence that can lag years behind clinical need.

These problems compound. The same data failure that slows discovery can delay the right patient from reaching the right trial. All five bottlenecks trace back to the same root cause: There is no unified data foundation that can reason across the continuum.

What ‘agentic’ actually means here and a foundation-first approach

Traditional AI answers a question. Agentic AI plans and executes across multiple steps without a person needing to trigger each one.

However, AI is only as effective as the data foundation that governs it. Cancer data isn't a spreadsheet. Genomic sequences, pathology images, unstructured notes, claims records and wearable signals are complex and multimodal in nature. They carry valuable insights needed to move care forward but only when organizations can ingest, unify and reason over them together. A genomic variant needs clinical context. An imaging finding gains meaning alongside molecular markers and treatment history.

Consider an agent that receives a sequencing result, compares it with similar patient profiles, identifies open trials, models feasibility and prepares a tumor board summary — all from a single data event. The convergence of multimodal data infrastructure, foundation models and governed AI platforms is making this operationally viable.

But agentic capabilities acting on regulated data and workflows require a different level of scrutiny. Governance and security must be built into your agentic strategy from the ground up — not bolted on afterward — to safeguard protected health information (PHI) and support compliance with industry standards such as HIPAA. The impact of an incorrect answer in the clinical context carries implications far beyond an incorrect dashboard and can affect patient outcomes. This means auditability, access controls, agent guardrails and clear rules for when to keep humans in the loop are mission critical and should be considered at the front end of the agentic journey.

Where agentic AI is creating real impact

Discovery and research

The first bottleneck — siloed molecular and genomic data — is where agentic AI is showing early promise. Oncology drug development has a persistent attrition rate above 95%, with an estimated $50 billion to $60 billion spent annually on failed oncology trials, according to a 2023 study in JAMA Network Open .

Agentic systems can traverse genomic, structural and literature data in one reasoning chain. They can surface viable candidates earlier, flag likely failure modes before the lab and continuously incorporate new findings. The practical result is a faster path from hypothesis to viable compound, giving research teams more time to spend on the strongest opportunities.

Screening and early detection

The second bottleneck — multimodal signals that never converge — creates a deeply human problem. After a biopsy, patients can spend two to six weeks waiting for pathology, with longer delays when molecular biomarker testing or genomic sequencing is required. During that time, they are left in uncertainty, unable to plan or make sense of what comes next, not knowing whether they are positive or negative for the disease.

AI is compressing parts of these workflows. AI-powered imaging triage can reduce turnaround from days to minutes by prioritizing time-critical findings; digital pathology can transform slide analysis — accelerating previously manual workflows with computational science. A large real-world U.S. screening study found that an AI-supported workflow identified 21.6% more breast cancers than standard mammography review .

The agentic opportunity lies in convergence: an imaging finding, biomarker result, EHR risk flag and family history pattern considered together, replacing the sequential manual assembly that creates the wait. The clinical impact is faster diagnosis. The human impact is fewer weeks in limbo.

Diagnosis and treatment planning

Tumor boards remain among oncology's most important and most manual workflows. Clinicians assemble genomic profiles, pathology, imaging and treatment histories from disparate systems, often under intense time pressure.

An agentic system triggered by a new diagnostic result can gather those sources, structure a patient brief, cross-reference trial eligibility and surface the material...